新辅助-话题@MedSci

#新辅助#

321篇内容 | 5207人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1678709, encodeId=56d216e87096a, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=DCR: 慢性肾脏病对接受新辅助放化疗治疗的局部晚期直肠癌患者的预后影响, objectType=article, longId=265010, objectId=4dc6265010cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dc6265010cc, replyNumber=0, likeNumber=61, createdTime=2022-05-11, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dc6265010cc, moduleTitle=DCR: 慢性肾脏病对接受新辅助放化疗治疗的局部晚期直肠癌患者的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dc6265010cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678721, encodeId=3d0e16e8721ec, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, objectType=article, longId=295135, objectId=2c9b295135ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c9b295135ea, replyNumber=0, likeNumber=77, createdTime=2022-06-01, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c9b295135ea, moduleTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c9b295135ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678746, encodeId=467a16e87462b, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, objectType=article, longId=727595, objectId=086be27595c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=086be27595c5, replyNumber=0, likeNumber=88, createdTime=2022-10-14, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=086be27595c5, moduleTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=086be27595c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678713, encodeId=36c016e8713ed, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, objectType=article, longId=291956, objectId=2f9f2919568c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f9f2919568c, replyNumber=0, likeNumber=93, createdTime=2022-08-30, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f9f2919568c, moduleTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f9f2919568c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678695, encodeId=18ad16e8695f1, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=2021CSCO：免疫辅助及新辅助治疗在NSCLC中的新探索, objectType=article, longId=217843, objectId=313621e843e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313621e843e5, replyNumber=0, likeNumber=77, createdTime=2022-01-13, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313621e843e5, moduleTitle=2021CSCO：免疫辅助及新辅助治疗在NSCLC中的新探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313621e843e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678733, encodeId=44ee16e8733a4, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=116, createdTime=2022-04-01, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678703, encodeId=b70916e870390, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期, objectType=article, longId=220045, objectId=0f6e220045c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f6e220045c5, replyNumber=0, likeNumber=78, createdTime=2021-11-17, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f6e220045c5, moduleTitle=CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f6e220045c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678725, encodeId=a09d16e8725bc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=肺癌新辅助治疗疗效如何进行病理评估？总结共识的9大要点, objectType=article, longId=299329, objectId=1ea129932930, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ea129932930, replyNumber=0, likeNumber=85, createdTime=2022-09-21, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ea129932930, moduleTitle=肺癌新辅助治疗疗效如何进行病理评估？总结共识的9大要点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ea129932930)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678706, encodeId=bb1c16e8706b3, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=新辅助化疗在卵巢内胚窦瘤保留生育功能中的价值, objectType=article, longId=220975, objectId=58582209e5bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58582209e5bb, replyNumber=0, likeNumber=70, createdTime=2022-11-08, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58582209e5bb, moduleTitle=新辅助化疗在卵巢内胚窦瘤保留生育功能中的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58582209e5bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678736, encodeId=f40f16e873622, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology：MRI在预测乳腺癌患者新辅助化疗病理完全缓解的价值, objectType=article, longId=723939, objectId=1761e2393961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1761e2393961, replyNumber=0, likeNumber=121, createdTime=2023-02-28, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1761e2393961, moduleTitle=European Radiology：MRI在预测乳腺癌患者新辅助化疗病理完全缓解的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1761e2393961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678748, encodeId=e36016e8748e1, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=ASCO 2022 | 新辅助化疗对Borrmann Ⅳ型胃癌疗效有限, objectType=article, longId=728530, objectId=7500e285305a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7500e285305a, replyNumber=0, likeNumber=109, createdTime=2023-02-25, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7500e285305a, moduleTitle=ASCO 2022 | 新辅助化疗对Borrmann Ⅳ型胃癌疗效有限, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7500e285305a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678723, encodeId=a43e16e87238a, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology：使用CT和肿瘤标记物评估胰腺癌新辅助治疗后的可切除性, objectType=article, longId=295476, objectId=56f82954e61f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f82954e61f, replyNumber=0, likeNumber=73, createdTime=2022-12-21, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f82954e61f, moduleTitle=European Radiology：使用CT和肿瘤标记物评估胰腺癌新辅助治疗后的可切除性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f82954e61f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678701, encodeId=508516e8701aa, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Front Oncol：新辅助化疗(NAC)后射频消融(RFA)改善可消融的结直肠癌肝转移（CRLM）患者的预后, objectType=article, longId=219341, objectId=c7332193416b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7332193416b, replyNumber=0, likeNumber=77, createdTime=2021-11-24, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7332193416b, moduleTitle=Front Oncol：新辅助化疗(NAC)后射频消融(RFA)改善可消融的结直肠癌肝转移（CRLM）患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7332193416b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678732, encodeId=c52a16e87325c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌, objectType=article, longId=301277, objectId=a25e3012e7e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a25e3012e7e9, replyNumber=0, likeNumber=94, createdTime=2022-04-14, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a25e3012e7e9, moduleTitle=重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a25e3012e7e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678720, encodeId=db1016e8720cf, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, objectType=article, longId=295073, objectId=a9a02950e37b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a02950e37b, replyNumber=0, likeNumber=76, createdTime=2022-08-01, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a02950e37b, moduleTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a02950e37b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678739, encodeId=483f16e8739cd, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=95, createdTime=2022-03-26, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678697, encodeId=b85216e86976e, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , objectType=article, longId=218140, objectId=973121814015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=973121814015, replyNumber=0, likeNumber=66, createdTime=2022-06-07, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=973121814015, moduleTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973121814015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678708, encodeId=2f9116e8708aa, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Eur Urol：不同分子亚型的尿路上皮癌对新辅助化疗的差异反应分析, objectType=article, longId=221754, objectId=a389221e54ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a389221e54ed, replyNumber=0, likeNumber=74, createdTime=2022-11-19, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a389221e54ed, moduleTitle=Eur Urol：不同分子亚型的尿路上皮癌对新辅助化疗的差异反应分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a389221e54ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678740, encodeId=ad2916e8740d2, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Br J Cancer：可预测直肠癌患者对新辅助治疗反应性的预测模型, objectType=article, longId=724004, objectId=857ee2400404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=857ee2400404, replyNumber=0, likeNumber=74, createdTime=2023-03-06, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=857ee2400404, moduleTitle=Br J Cancer：可预测直肠癌患者对新辅助治疗反应性的预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=857ee2400404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678696, encodeId=3b3e16e869659, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART), objectType=article, longId=218117, objectId=5c0921811e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c0921811e5f, replyNumber=0, likeNumber=73, createdTime=2022-03-09, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c0921811e5f, moduleTitle=Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c0921811e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新辅助

2020-05-29

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

DCR: 慢性肾脏病对接受新辅助放化疗治疗的局部晚期直肠癌患者的预后影响

2022-05-11

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效

2022-06-01

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果

2022-10-14

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析

2022-08-30

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

2021CSCO：免疫辅助及新辅助治疗在NSCLC中的新探索

2022-01-13

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-04-01

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期

2021-11-17

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

肺癌新辅助治疗疗效如何进行病理评估？总结共识的9大要点

2022-09-21

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

新辅助化疗在卵巢内胚窦瘤保留生育功能中的价值

2022-11-08

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology：MRI在预测乳腺癌患者新辅助化疗病理完全缓解的价值

2023-02-28

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

ASCO 2022 | 新辅助化疗对Borrmann Ⅳ型胃癌疗效有限

2023-02-25

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology：使用CT和肿瘤标记物评估胰腺癌新辅助治疗后的可切除性

2022-12-21

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Front Oncol：新辅助化疗(NAC)后射频消融(RFA)改善可消融的结直肠癌肝转移（CRLM）患者的预后

2021-11-24

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌

2022-04-14

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性

2022-08-01

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-03-26

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST

2022-06-07

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Eur Urol：不同分子亚型的尿路上皮癌对新辅助化疗的差异反应分析

2022-11-19

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Br J Cancer：可预测直肠癌患者对新辅助治疗反应性的预测模型

2023-03-06

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART)

2022-03-09

科室
- - 订阅+
  - 更多科室
工具
服务